Comparative Pharmacology
Head-to-head clinical analysis: MICROGESTIN FE 1 5 30 versus MICROGESTIN FE 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROGESTIN FE 1 5 30 versus MICROGESTIN FE 1 20.
MICROGESTIN FE 1.5/30 vs MICROGESTIN FE 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination oral contraceptive: ethinyl estradiol (estrogen) and norethindrone acetate (progestin) suppress gonadotropin (FSH, LH) release, preventing ovulation; increase cervical mucus viscosity, inhibiting sperm penetration; alter endometrial development, reducing implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone acetate (progestin). Suppresses gonadotropins via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
Prevention of pregnancyTreatment of moderate acne vulgaris in women >=15 years who have achieved menarche and are not pregnant or otherwise contraindicatedTreatment of heavy menstrual bleeding (off-label)Emergency contraception (off-label)
Prevention of pregnancyTreatment of moderate acne vulgaris (in females ≥15 years who have achieved menarche)
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily for 28-day cycles (21 active tablets + 7 ferrous fumarate tablets).
One tablet orally once daily, containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets) or continuous cycling per prescribing information.
None Documented
None Documented
Norethindrone: 6-8 hours (terminal); Ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; dosing interval suitable for once-daily administration.
Norethindrone: 5-14 hours (mean 8 hours); Ethinyl estradiol: 12-24 hours (mean 18 hours); Steady-state in 5-7 days
Ethinyl estradiol: primarily metabolized via CYP3A4; undergoes first-pass metabolism in gut and liver. Norethindrone acetate: deacetylated to norethindrone, metabolized mainly via reduction and conjugation (glucuronidation, sulfation), partly by CYP3A4.
Primarily hepatic via CYP3A4. Norethindrone acetate undergoes reduction and conjugation; ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Norethindrone: 50-60% renal (as metabolites), 20-40% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal (as glucuronide/sulfate conjugates).
Renal: ~50-60% as metabolites; Fecal: ~30-40% as metabolites; Biliary: minor; <1% unchanged
Norethindrone: ~97% albumin and SHBG; Ethinyl estradiol: ~98% albumin (induces SHBG synthesis).
Norethindrone: 61% to albumin, 36% to SHBG; Ethinyl estradiol: 98% to albumin
Norethindrone: 2-5 L/kg (wide distribution, including breast tissue and adipose); Ethinyl estradiol: 2-4 L/kg (extensive distribution into reproductive tissues).
Norethindrone: 2.1 L/kg; Ethinyl estradiol: 2.8 L/kg
Norethindrone: ~64% (oral, first-pass metabolism); Ethinyl estradiol: ~40-45% (oral, first-pass metabolism).
Oral: Norethindrone ~65%; Ethinyl estradiol ~40-45%
No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). Not recommended in severe impairment (eGFR <30 mL/min/1.73 m²) due to limited data.
No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 mL/min) or end-stage renal disease; use caution due to potential for estrogen accumulation and metabolic effects.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A (mild impairment), use with caution; no specific dose adjustment established, but may increase risk of adverse effects.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). For Child-Pugh Class A or B, use only if benefits outweigh risks; monitor for adverse effects; consider alternative contraception due to altered hormone metabolism.
Approved for postmenarcheal adolescents. Dose same as adults: one tablet orally once daily for 28-day cycles. Not indicated for premenarcheal patients.
Post-menarchal pediatric patients: Same dosing as adults. Safety and efficacy established in adolescents; use according to standard adult regimen.
Not indicated for use in women over 65 years due to lack of efficacy and safety data; increased risk of thromboembolic events and cardiovascular disease outweighs potential benefit.
Not indicated for postmenopausal women; no specific dosing recommendations. Use caution in elderly if prescribed off-label due to increased risk of thromboembolic events, cardiovascular disease, and malignancy.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (>=15 cigarettes/day). Women >=35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women who use combination oral contraceptives should be strongly advised not to smoke.
["Thrombotic disorders (venous thromboembolism, arterial thrombosis, stroke, MI)","Carcinoma of breast/cervix","Hepatic disease (jaundice, tumors)","Elevated blood pressure","Gallbladder disease","Carbohydrate/lipid effects","Headache/migraine","Vaginal bleeding irregularities","Depression","Hereditary angioedema","Chloasma","Pregnancy loss"]
["Increased risk of thromboembolic disorders (e.g., stroke, MI, VTE), especially in smokers and women with hypertension, diabetes, or hyperlipidemias","Elevated risk of cervical and breast cancer","Hepatic neoplasia (benign and malignant)","Gallbladder disease","Carbohydrate and lipid metabolism alterations","Hypertension","Headache/migraine","Irregular bleeding","Depression","Contact lens intolerance","Possible decreased efficacy with hepatic enzyme inducers","Discontinue if jaundice, visual disturbances, or thromboembolic symptoms occur"]
["Thrombophlebitis or thromboembolic disorders","History of DVT/PE","Cerebrovascular or coronary artery disease","Known or suspected breast carcinoma","Carcinoma of endometrium or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma/carcinoma","Known or suspected pregnancy","Hypersensitivity to any component","Smoking in women >=35 years","Uncontrolled hypertension","Diabetes with vascular involvement","Major surgery with prolonged immobilization"]
["Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease (current or history)","Known or suspected breast carcinoma","Endometrial carcinoma or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use","Hepatic adenoma or carcinoma (current or history)","Known or suspected pregnancy","Heavy smoking (≥15 cigarettes/day) and age >35 years","Uncontrolled hypertension","Diabetes with vascular involvement","Migraine with focal neurological symptoms (current or history)"]
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit juice may increase estrogen levels but no specific restriction is required. Iron tablets should be taken on an empty stomach for best absorption, but can be taken with food if GI upset occurs.
No specific food restrictions. Grapefruit juice may modestly increase estrogen levels but is not contraindicated. High-fat meals may increase estrogen absorption. Calcium-rich foods or supplements may reduce iron absorption from placebo tablets; separate intake by several hours.
FDA Pregnancy Category X. First trimester: No increased risk of major birth defects from inadvertent use, but post-fertilization effects are theoretical. Contraindicated in pregnancy due to estrogen component and progestin exposure. Second/third trimester: Irrelevant as drug is contraindicated; no fetal exposure studies. Use in pregnancy may cause fetal harm: possible congenital anomalies (limb defects, heart defects) and adverse outcomes (low birth weight, premature birth, neonatal withdrawal) with prolonged exposure.
FDA Pregnancy Category X. Estrogens and progestins are contraindicated in pregnancy due to risk of fetal harm. Epidemiological studies have not revealed an increased risk of birth defects in women who inadvertently used combined oral contraceptives during early pregnancy. However, use of progestins alone during the first trimester of pregnancy is associated with genital abnormalities in female fetuses, including hypospadias and mild clitoral hypertrophy. Post-fertilization effects: no evidence of increased risk of spontaneous abortion or low birth weight with inadvertent use during early pregnancy. Second and third trimesters: no therapeutic indication; potential for estrogenic effects on fetal development, but data are limited due to contraindication.
Small amounts of ethinyl estradiol and norethindrone acetate are excreted in breast milk (estimated ~0.1% of maternal dose). M/P ratio not established. No adverse effects on nursing infant or milk production reported with combined oral contraceptives; however, WHO recommends avoiding combined OCs during lactation until weaning or at least 6 months postpartum due to theoretical risk of estrogen affecting milk production. Use caution; consider progestin-only alternative.
Small amounts of contraceptive steroids and their metabolites are excreted in human milk, with an estimated infant dose of 0.1% to 1% of maternal dose per kg/day. The M/P ratio for norethindrone is approximately 0.6. Breastfeeding safety: use is not recommended while breastfeeding, especially with early postpartum use, due to potential reduction in milk production and content, as well as unknown long-term effects on infant development. Alternative contraception methods should be considered.
Contraindicated in pregnancy; no dose adjustment applicable. If pregnancy occurs, discontinue drug immediately. No pharmacokinetic data indicating need for dose changes in pregnancy because drug is not used during pregnancy.
No dosing adjustments recommended because the drug is contraindicated in pregnancy. If inadvertently used, the drug should be discontinued immediately. No clinical studies have established safe or effective dosing regimens during pregnancy.
Category C
Category C
MICROGESTIN FE 1.5/30 contains norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, plus ferrous fumarate (iron) tablets. The iron tablets are not part of the contraceptive regimen and should be taken only if iron deficiency is a concern. Because it is a combination oral contraceptive (COC), it has higher estrogen content compared to low-dose pills, which may increase the risk of thromboembolism. It is indicated for contraception and may also be used for menstrual disorders. The ring in the package is a placebo indicator; be aware that patients may confuse the iron tablets for active pills.
Contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg with ferrous fumarate 75 mg as placebo tablets. Iron supplementation may improve hematologic parameters in anemic patients. Bleeding irregularities are common in first 3-6 months; counsel on adherence to prevent breakthrough bleeding. Caution in patients with migraine with aura, history of VTE, or smokers over 35. CYP3A4 inducers like rifampin may reduce efficacy; consider alternative contraception.
Take one active pill at the same time each day, followed by the brown iron tablets during the last 7 days of the pack.If you miss a dose, follow the package instructions: take the missed pill as soon as remembered, and use backup contraception if more than one pill is missed.Smoking increases the risk of serious cardiovascular side effects from birth control pills, especially if you are over 35.Common side effects include nausea, breast tenderness, and breakthrough bleeding, which often resolve within a few months.This pill does not protect against HIV or other sexually transmitted infections.
Take one tablet daily at the same time each day, preferably with food to reduce nausea.The last 7 tablets (brown) contain iron and are inactive; continue taking them to maintain the habit.Bleeding may be irregular initially; report heavy or prolonged bleeding to your healthcare provider.Do not smoke while taking this medication, especially if over 35, as it increases clot risk.Use additional non-hormonal contraception (e.g., condoms) if you miss a pill or have vomiting/diarrhea.Store at room temperature away from moisture and heat.